Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Michael Anthony who wrote (224)	1/11/1998 4:41:00 PM
From: Ian@SI	Respond to of 1321

Michael, In: 207.183.153.33 George McGeary indicated that trials wouldn't end until this fall, FDA application in June,99 and approval by YE 99. Hopefully, the schedule will be advanced but that was IR's word last year. Ian.

To: Michael Anthony who wrote (224)	1/11/1998 4:57:00 PM
From: Joe Stephenson	Read Replies (1) \| Respond to of 1321

Michael: If you are refering to QLT's Phase III trials for ARMD, I believe they started in Sept. 97, after QLT announced successful completion of their patient accrual. From what I understand, it's about a 2 year approval process after Phase III begins, BUT, preliminary data can be analysed and subsequently released after the last patient has been followed for 12 months, ie., September 1998. I expect we'll hear about those preliminary results late this year or early '99. What I don't know is, whether the FDA can grant early approval on preliminary results, or if QLT will have to wait until the entire process is finished. If you or anyone else has any further insight, it would be worth posting. Also, I would think we'll see late stage cancer approved by the FDA later this year, as long as things go well at the March ODAC hearings. Cheers, Joe